NCT04525859View on ClinicalTrials.gov

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Malignant Pleural Mesothelioma
Interventions
BIOLOGICAL

Safety

See previous Safety group description

BIOLOGICAL

Expansion Cohort

See previous Expansion Cohort

Trial Locations (1)

10029

Icahn School of Medicine Mount Sinai, New York

Sponsors

Lead Sponsor

Oncovir, Inc.
All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Oncovir, Inc.

INDUSTRY

NCT04525859 - Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter